UROMUNE (MV140) in recurrent urinary tract infections

CistitisAugust 2020

A systematic review on the role of UROMUNE (MV140) in the prevention of rUTI (recurrent urinary tract infections) has been published. The study, led by Dr. J. Curtis Nickel (Queen's University, Canada), has taken into account published clinical data conducted with this vaccine. UROMUNE (MV140) is a sublingual vaccine developed and manufactured by INMUNOTEK that includes the main bacteria that cause recurrent urinary infections.
More info

INMUNOTEK´s research in Allergy Virtual Issue

March 2020

The research study on the effect of aluminum in the new allergoid-mannan conjugates carried out at the Complutense University of Madrid and INMUNOTEK published in Allergy, has been selected to be included in the opening issue of the Virtual Issue collection, aimed to promote the dissemination of outstanding studies.
More info

Financial Times features INMUNOTEK

Financial TimesDecember 2019

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.
More info

National Innovation Award to INMUNOTEK

logo PNID2November 2019

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of "Small and Medium-Sized Enterprise".
More info

INMUNOTEK awarded as "Best SME of the Year"

Cepyme Premio 2019November 2019

INMUNOTEK has been awarded as the Best SME of the Year 2019 by CEPYME (Spanish Confederation of Small and Medium-Sized Enterprises). This award recognizes Business Excellence under the criteria of business activity, innovation, internationalization and job creation. The award ceremony was chaired by the Spanish Minister of Economy and Business, Nadia Calviño, the President of CEPYME, Gerardo Cuerva and the CEO of Santander Bank, Rami Aboukhair, as sponsor of the award.
More info

BMC publishes a new article on UROMUNE

CistitisOctober 2019

A recent publication in BMC Infectious Diseases journal indicates that UROMUNE decreases the recurrence of urinary tract infections. The study, conducted on a total of 784 patients in the hospitals of Mataró and Moisés Broggi (Barcelona) between 2011-2017, concludes that treatment with UROMUNE was highly effective to reduce the number of episodes of urinary tract infections at three and six months of follow-up. UROMUNE is a polybacterial mucosal vaccine developed by INMUNOTEK that is administered by a sublingual spray.
More info

Alum impairs the effect of mannan-allergoid conjugates

October 2019

The effect of aluminum hydroxide on the tolerogenic properties of dendritic cells induced by allergoids coupled to mannan has been published in Allergy with the title "Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs". The study has been carried out at the School of Chemistry of the Complutense University of Madrid with the collaboration of INMUNOTEK.
More info

Trained Immunity-based Vaccines in El Escorial Summer Courses

Cursos verano El EscorialJuly 2019

Within the Summer Courses of El Escorial organized by the Complutense University of Madrid, the one entitled "Trained immunity-based vaccines: the innate immune memory working towards  antiinfectious immunotherapy" was held in Madrid during 11-12th of July under the direction of Dr. Silvia Sánchez Ramón (Immunology, San Carlos Clinical Hospital, Madrid) and Dr. Laura Conejero Hall (INMUNOTEK), Scientific Secretariat. The course, sponsored by INMUNOTEK, has combined basic aspects of the mechanisms of action of trained immunity, with the clinical outcome in recurrent respiratory and urinary tract infections.
More info

Immunomodulatory effect of oral epithelial cells

Frontiers Immunology_oral epithelial cells_3July 2019

Frontiers in Immunology publishes the article "Human Oral Epithelial Cells Impair Bacteria-Mediated Maturation of Dendritic Cells and Render T Cells Unresponsive to Stimulation". This research reveals the immunomodulation exerted by the epithelial cells of the oral cavity either on cells of innate immunity stimulated with bacteria and/or on cells (T lymphocytes) of adaptive immunity. The research carried out in the School of Medicine of the Complutense University of Madrid has had the participation of INMUNOTEK.
More info

The olive tree protagonist in the "Eliseo Subiza" Botanical Day

Jornada Eliseo Subiza_olivoMay 2019

The XXII Botanical Identification Seminar Day "Eliseo Subiza" was dedicated to the olive tree and took place in Toledo. This initiative of the Hospital Virgen del Valle (Toledo) has the collaboration of INMUNOTEK and is aimed to perform a botanical training of young allergists in main local allergenic plants. Through field trips with botanical experts and aerobiological lectures, each year is dedicated to special plant. The olive tree is a tree of great allergological interest as a cause of pollinosis in Spain since its pollen is very allergenic and affects a large number of patients.
More info